Zymeworks (ZYME) EBIT (2021 - 2026)

Zymeworks has disclosed EBIT across 6 years of filings, most recently posting -$47.1 million for Q1 2026.

• EBIT for Q1 2026 came in at -$47.1 million, down 83.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$114.1 million (up 8.7% YoY), and the FY2025 annual result was -$92.5 million, up 32.5% from the prior year.
• EBIT came in at -$47.1 million for Q1 2026 at Zymeworks, down from -$44.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $319.4 million in Q4 2022 to a low of -$72.7 million in Q1 2022.
• The 5-year median for EBIT is -$34.2 million (2024), against an average of -$16.7 million.
• Across the five-year window, EBIT jumped 881.89% in 2022 and tumbled 107.33% in 2023, its largest moves.
• Zymeworks' EBIT stood at $319.4 million in 2022, then plunged by 107.33% to -$23.4 million in 2023, then rose by 5.14% to -$22.2 million in 2024, then slumped by 98.73% to -$44.2 million in 2025, then retreated by 6.72% to -$47.1 million in 2026.
• The last three EBIT figures came in at -$47.1 million (Q1 2026), -$44.2 million (Q4 2025), and -$22.1 million (Q3 2025), per Business Quant data.